Ceptaris

Actelion Closes Acquisition of Privately-held Ceptaris Therapeutics Adding Valchlor to Actelion's Product Portfolio Read more here

Galderma Receives FDA Approval of Mirvaso® Read more here

Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics Read more here

Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride Read more here

Ceptaris Announces Publication in JAMA Dermatology of Positive Clinical Results Read more here

Ceptaris Secures $10 Million in Series D-1 Financing Read more here

Ceptaris Secures $15M in Venture Debt Financing Read more here

Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel Read more here

Yaupon Changes Name to Ceptaris Therapeutics, Inc. Read more here